Blinatumomab (CD19/CD3E) - Research Grade Biosimilar

• Background:

  Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .Blinatumomab is manufactured by Amgen Inc.and marketed under the brand Blincyto™.Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.

• Immunogen:

  Mus musculus / CD19/CD3E [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  (scFv-kappa-heavy) - (scFv-heavy-kappa)

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3, CD19/CD3E, CD19/CD3E